Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Chun, Sang Y ^a   Johnson, Craig ^a   Washburn, Joseph G ^a   Cruz Correa, Marcia R ^b   Dang, Duyen T ^c   Dang, Long H ^d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARDIOLIPIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER CELL; COLON CANCER; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; ONCOGENE K RAS; PHOSPHOLIPID SYNTHESIS; CELL STRAIN HCT116; COLON TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MITOCHONDRION; OXYGEN CONSUMPTION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOCHONDRIA; MUTAGENESIS, SITE-DIRECTED; OXYGEN CONSUMPTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78149341677     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-293     Document Type: Article

References (38)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989, 49(17):4682-9.
2. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005, 1756(2):127-44.
3. Weinberg RA. ras Oncogenes and the molecular mechanisms of carcinogenesis. Blood 1984, 64(6):1143-5.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
5. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005, 102(17):5992-7. 10.1073/pnas.0502267102, 1087961, 15840712.
6. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47. 10.1038/nrc704, 11902584.
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-32. 10.1038/nrc1187, 13130303.
8. Ema M, et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997, 94(9):4273-8. 10.1073/pnas.94.9.4273, 20712, 9113979.
9. Flamme I, et al. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 1997, 63(1):51-60. 10.1016/S0925-4773(97)00674-6, 9178256.
10. Karni R, et al. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem 2002, 277(45):42919-25. 10.1074/jbc.M206141200, 12200433.
11. Richard DE, et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999, 274(46):32631-7. 10.1074/jbc.274.46.32631, 10551817.
12. Kamura T, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000, 97(19):10430-5. 10.1073/pnas.190332597, 27041, 10973499.
13. Ohh M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2(7):423-7. 10.1038/35017054, 10878807.
14. Mylonis I, et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 2006, 281(44):33095-106. 10.1074/jbc.M605058200, 16954218.
15. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007, 26(2):333-9. 10.1007/s10555-007-9063-1, 17458506.
16. Sowter HM, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63(19):6130-4.
17. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85(12):1301-7. 10.1007/s00109-007-0281-3, 18026916.
18. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007, 39(3):231-4. 10.1007/s10863-007-9081-2, 17551816.
19. Agrawal A, et al. Normoxic stabilization of HIF-1alpha drives glycolytic metabolism and regulates aggrecan gene expression in nucleus pulposus cells of the rat intervertebral disk. Am J Physiol Cell Physiol 2007, 293(2):C621-31. 10.1152/ajpcell.00538.2006, 17442734.
20. Dang DT, et al. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006, 66(3):1684-936. 10.1158/0008-5472.CAN-05-2887, 16452228.
21. Papandreou I, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3(3):187-97. 10.1016/j.cmet.2006.01.012, 16517406.
22. Kim JW, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3(3):177-85. 10.1016/j.cmet.2006.02.002, 16517405.
23. Fukuda R, et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129(1):111-22. 10.1016/j.cell.2007.01.047, 17418790.
24. Mashima T, et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005, 97(10):765-77. 10.1093/jnci/dji133, 15900046.
25. Vreken P, et al. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 2000, 279(2):378-82. 10.1006/bbrc.2000.3952, 11118295.
26. Gu Z, et al. Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. Mol Microbiol 2004, 51(1):149-58. 10.1046/j.1365-2958.2003.03802.x, 14651618.
27. Cooke D, O'Kennedy R. Comparison of the tetrazolium salt assay for succinate dehydrogenase with the cytosensor microphysiometer in the assessment of compound toxicities. Anal Biochem 1999, 274(2):188-94. 10.1006/abio.1999.4274, 10527515.
28. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-14. 10.1126/science.123.3191.309, 13298683.
29. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006, 9(6):419-20. 10.1016/j.ccr.2006.05.012, 16766260.
30. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr 2007, 39(3):251-7. 10.1007/s10863-007-9085-y, 17624581.
31. Li F, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005, 25(14):6225-34. 10.1128/MCB.25.14.6225-6234.2005, 1168798, 15988031.
32. Telang S, et al. The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 2007, 6:77. 10.1186/1476-4598-6-77, 2222650, 18053146.
33. de Groof AJ, et al. Increased OXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg phenotype. Mol Cancer 2009, 8:54. 10.1186/1476-4598-8-54, 2734543, 19646236.
34. Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008, 26(10):1582-4. 10.1200/JCO.2007.15.3700, 18316790.
35. Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-7. 10.1200/JCO.2006.10.5437, 17664471.
36. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2(10):803-11. 10.1038/nrd1199, 14526383.
37. Chun SY, et al. CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. Oncogene 2007, 26(32):4725-9. 10.1038/sj.onc.1210258, 17297462.
38. Folch J, Lees M, Stanley Sloane GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226(1):497-509.